Nash P, et al. - Researchers herein evaluated the 52-week effectiveness and safety of secukinumab self-administration by autoinjector in cases having active psoriatic arthritis (PsA) in the FUTURE 3 study. Sustained improvements in signs and symptoms by secukinumab were noted in active PsA patients. Autoinjector was seen to be highly accepted. Secukinumab was seen to be well tolerated and the safety profile was consistent with that reported previously.